Thermo Fisher Scientific Financial Statements FY2024-FY2026Q3

Thermo Fisher Scientific Inc. (TMO) Financial Statements in Beancount — Open Ledger

Thermo Fisher Scientific's income statement and balance sheet, FY2024 through FY2026Q3, as a public, auditable plain-text Beancount ledger — reconstructed line by line from the company's own Form 10-K and 8-K filings and version-controlled in git. Part of the Open Ledger project on beancount.io.

Browse it live: beancount.io/ledger/open_ledger/thermo-fisher

Latest analysis: Thermo Fisher Q3 2026 Earnings: 6% Organic Growth, $6.68 EPS and a $9.1B Clario Bet

Key Figures

Amounts in MUSD (millions of US dollars), exactly as the ledger records them.

What's Inside

Fiscal years end December 31; quarters end on the Saturday nearest the calendar quarter end (Q3 2026 ended September 26, 2026). All figures sourced from Thermo Fisher Scientific Inc. Form 10-K filings and the Q3 2026 earnings Form 8-K (SEC EDGAR, CIK 0000097745).

Quick Start

uvx --from beancount bean-check main.bean
uvx --from beanquery bean-query main.bean \
  "SELECT year, sum(position) WHERE account ~ '^Income:Revenue' GROUP BY year ORDER BY year"

Zero output from bean-check means the ledger is internally consistent: every
income statement sums to zero and every balance-sheet snapshot reconciles to
the filed totals. The query prints revenue by calendar year; income is a
credit, so it shows as a negative number. Open main.bean in Fava
or import it into beancount.io to explore it visually.

Methodology

• Balance sheet — pad / balance directives assert each period-end
  figure against the filing named in that period file's source banner.
• Income statement — one zero-sum transaction per period: Income
  negative (credit), Expenses positive (debit), with the arithmetic check in
  a comment directly above it.
• Unit — MUSD; 12,137 MUSD means 12,137 million US dollars.
• Additional accounts — Assets:Current:Inventory, Equity:TreasuryStock,
  Equity:NoncontrollingInterests, Equity:UndisaggregatedParent,
  Equity:Temporary:RedeemableNoncontrollingInterests,
  Expenses:AmortizationOfAcquiredIntangibles,
  Expenses:ImpairmentsAndRestructuring, Expenses:Interest, opened beyond the
  standard chart (see each account's open line in main.bean).
• Condensed quarter — the Q3 2026 8-K prints only the equity total, so the
  whole $54,767M sits on Equity:UndisaggregatedParent and the component
  equity accounts are asserted at zero, never estimated; accounts payable and
  contract liabilities are likewise folded into Liabilities:Current:Other.
• Rounding — the filings' printed totals trail their components by $1M in a
  few places; the residual lines absorb the difference with a comment naming
  both sums, and every income statement still offsets at exactly the filed net
  income.

Analysis

• Thermo Fisher Q3 2026 Earnings: 6% Organic Growth, $6.68 EPS and a $9.1B Clario Bet — FY2026Q3

Corrections

Found a figure that does not match the filing? Email
[email protected] with the period, the account
and the filing page. Corrections are committed with the source cited.

About Open Ledger

Open Ledger is a growing library of public-company financial statements
published as plain-text accounting at
beancount.io/ledger — git-versioned, diffable
across companies, and auditable against primary filings. Read the analysis
behind the numbers on the beancount.io blog.

Disclaimer

This ledger is an independent reconstruction of Thermo Fisher Scientific Inc.'s publicly filed
financial statements, provided for educational and informational purposes
only. It is not investment, financial, legal, tax, or accounting advice, and
is not an offer or recommendation to buy or sell any security. Beancount.io is
not affiliated with, endorsed by, or sponsored by Thermo Fisher Scientific Inc.; all trademarks
belong to their respective owners. Figures may contain errors, omissions, or
simplifications and may lag the latest filings — the company's own regulatory
filings are the authoritative source. Provided "as is" without warranty of any
kind; use at your own risk.